Abstract: One of the leading causes of death worldwide is cancer. It is the unchecked development and spread of aberrant cells along with an imbalance in the process of apoptosis, or programmed cell death. Due to their significant pharmacological action, plants are the primary source of the majority of anti-cancer medications. These plant-based bimoleculars function via many mechanisms with the goal of triggering apoptosis in cancer cells. An increasing number of people are now interested in combining nanotechnology with medicine to develop nanomedicine, which seeks to diagnose and cure diseases with great efficiency and effectiveness. The word "nanomedicine" refers to the variety of multi-component drugs with nanometer-sized components used for disease treatment. ❖ As a result, the FDA has approved lipid-based nanoparticular delivery systems for use in clinical settings. Polymers are crucial in the design of nanocarriers for therapeutic deliveries since the major goal of introducing nanoscale drug delivery is to improve the pharmacological and pharmacokinetic profiles of therapeutic medicines. Low bioavailability drugs may be better absorbed by cells when delivered with a nano-specific drug delivery device. ❖ Surgery, chemotherapy, radiation therapy, hormonal therapy, and biological therapy are all used in the treatment of cancer. Today's cutting-edge co-therapy, known as photodynamic therapy, uses the interplay of light and photosensitizing chemicals to treat cancer. ❖ Gallic acid lipid nanoparticles with a targeting vector were developed in this study to increase the bioavailability and cellular penetration of gallic acid. The prepared nanoparticles were also characterised for use in various in-vitro studies and their effects on ehrlich ascites carcinoma-bearing female albino mice as an experimental model of cancer and the mechanism of anti-oxidants and anti-cancer effects. Gallic acid, a phenolic medication, is transformed into nanoparticles in the current study using single-emulsion evaporation, precipitation, and ...
No Comments.